Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benshang Li

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 24, 2024
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerabilityHui Li, Yao Chen, Ming Ding, et al.
Medrxiv : the Preprint Server for Health Sciences|October 14, 2024
Somatic mitochondrial DNA mutations are a source of heterogeneity among primary leukemic cellsKelly McCastlain, Catherine Welsh, Yonghui Ni, et al.
Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.
Blood|January 9, 2025
Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALLWeina Zhang, Jiaoyang Cai, Xiang Wang, et al.
Nature Medicine|May 12, 2015
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALLBenshang Li, Hui Li, Yun Bai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2022
Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II TrialTianyi Wang, Yanjing Tang, Jiaoyang Cai, et al.
Blood|November 8, 2019
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemiaBenshang Li, Samuel W Brady, Xiaotu Ma, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 24, 2024
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerabilityHui Li, Yao Chen, Ming Ding, et al.
Medrxiv : the Preprint Server for Health Sciences|October 14, 2024
Somatic mitochondrial DNA mutations are a source of heterogeneity among primary leukemic cellsKelly McCastlain, Catherine Welsh, Yonghui Ni, et al.
Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.
Blood|January 9, 2025
Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALLWeina Zhang, Jiaoyang Cai, Xiang Wang, et al.
Nature Medicine|May 12, 2015
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALLBenshang Li, Hui Li, Yun Bai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2022
Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II TrialTianyi Wang, Yanjing Tang, Jiaoyang Cai, et al.
Blood|November 8, 2019
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemiaBenshang Li, Samuel W Brady, Xiaotu Ma, et al.
Pageof 5